Perspectives

GastroPanel® for the private physicians

 

Prof. Francesco Di Mario

 

GastroPanel® represents a valuable diagnostic tool for private physicians seeking comprehensive information about their patients’ gastric health. This non-invasive test provides quantitative measurements of key biomarkers, including pepsinogen I (PGI), pepsinogen II (PGII), and gastrin-17 (G-17) and IgG against Hp which reflect the functional and morphological status of the gastric mucosa (1-4). By incorporating GastroPanel® testing into their practice, private physicians can accurately assess their patients’ risk of gastric diseases such as atrophic gastritis, peptic ulcer disease, GERD and gastric cancer, enabling early detection and targeted management strategies (4-7). Furthermore, GastroPanel® offers convenience and efficiency, allowing physicians to obtain valuable diagnostic information without the need for invasive procedures, thereby enhancing patient satisfaction and optimizing clinical decision-making in the private healthcare setting.

The private physician using GastroPanel® therefore has the possibility of having for the patient with symptoms affecting the upper digestive tract, a non-invasive and low-cost diagnosis of HP infection for which to plan eradication, the presence of gastroesophageal reflux disease from treatment with appropriate therapy, the identification of patients to undergo gastroscopy and finally the identification of patients who, having atrophic gastritis, do not require therapy with PPIs (8-10).

The recent introduction into clinical practice of the finger test called the GastroPanel® quick test allows us to have in real-time (within 20 minutes) all the information on the morphology and functions of the stomach while the patient is still in the clinic for the visit, thus allowing optimize diagnostic and therapeutic strategies.

 

References:

  1. Väänänen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003;15(8):885-891. doi:10.1097/01.meg.0000059429.46658.e4.
  2. Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci. 2009;54(11):2377-2384. doi:10.1007/s10620-008-0677-8.
  3. Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol. 2008;43(12):1448-1455. doi:10.1080/00365520802308083.
  4. Crafa P, Franceschi M, Rodriguez Castro KI, Barchi A, Russo M, Franzoni L, Antico A, Baldassarre G, Panozzo MP, Di Mario F. Functional Dyspesia. Acta Biomed. 2020 Jul 9;91(3):e2020069. doi: 10.23750/abm.v91i3.10150. PMID: 32921764; PMCID: PMC7716988.
  5. Di Mario F, Crafa P, Franceschi M, Rodriguez-Castro K, Baldassarre G, Ferronato A, Antico A, Panozzo MP, Franzoni L, Barchi A, Russo M, De Bortoli N, Ghisa M, Savarino E. Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. J Gastrointestin Liver Dis. 2021 Feb 12;30(1):25-29. doi: 10.15403/jgld-2952. PMID: 33548125.
  6. Cesario S, Scida S, Miraglia C, Barchi A, Nouvenne A, Leandro G, Meschi T, De’ Angelis GL, Di Mario F. Diagnosis of GERD in typical and atypical manifestations. Acta Biomed. 2018 Dec 17;89(8-S):33-39. doi: 10.23750/abm.v89i8-S.7963. PMID: 30561415; PMCID: PMC6502210.
  7. Di Mario F, Franzoni L, Franceschi M, Rodriguez-Castro KI, Russo M, Crafa P. Low levels of G17 and Barrett esophagus: a clinical relationship. Clin Chem Lab Med. 2022 Apr 28;60(7):e165-e167. doi: 10.1515/cclm-2022-0362. PMID: 35472009.
  8. Rodriguez K, Franceschi M, Ferronato A, Brozzi L, Antico A, Panozzo MP, Massella A, Pertoldi B, Morini A, Barchi A, Russo M, Crafa P, Franzoni L, Cuoco L, Baldassarre G, Di Mario F. A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy. Acta Biomed. 2022 Aug 31;93(4):e2022210. doi: 10.23750/abm.v93i4.12772. PMID: 36043968; PMCID: PMC9534244.
  9. Russo M, Rodriguez-Castro KI, Franceschi M, Ferronato A, Panozzo MP, Brozzi L, Di Mario F, Crafa P, Brandimarte G, Tursi A. Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers. Int J Mol Sci. 2023 Jan 25;24(3):2378. doi: 10.3390/ijms24032378. PMID: 36768710; PMCID: PMC9917011
  10. Di Mario F, Crafa P, Barchi A, Franzoni L, Franceschi M, Russo M, Bricca L, Brozzi L, Rodriguez Castro K, Rugge M. Pepsinogen II in gastritis and Helicobacter pylori infection. Helicobacter. 2022 Apr;27(2):e12872. doi: 10.1111/hel.12872. Epub 2022 Jan 8. PMID: 34997989.